Allogeneic Hematopoietic Cell Transplantation Using Post‐Transplant Cyclophosphamide in Patients With Large Paroxysmal Nocturnal Hemoglobinuria Clones
European Journal of Haematology · 2026-07 · 117 (1) · 154-160
DOI: 10.1111/ejh.70162 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 12.03.2026. Verfasst von Qiangsheng Weng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Cyclophosphamide, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for paroxysmal nocturnal hemoglobinuria (PNH). Post‐transplant cyclophosphamide (PTCy) has improved HSCT safety in other diseases, but its use in PNH is poorly characterized.
Methods
In this retrospective study, we analyzed outcomes of 19 patients with large PNH clones (≥ 50%) undergoing HSCT (2016–2025). Seven patients received a PTCy‐based platform (fludarabine‐busulfan‐cyclophosphamide conditioning with PTCy‐based graft‐versus‐host disease [GvHD] prophylaxis), whereas 12 received conventional prophylaxis.
Results
Patients' median age was 32 years; 68% had PNH with bone marrow failure. After a median follow‐up of 1349 days, overall and event‐free survival rates were 100% and 94.4%, respectively. All patients engrafted rapidly with full donor chimerism. No cases of chronic or grades II–IV acute GvHD occurred in the PTCy group (0/7); however, chronic GvHD and grades II–IV acute GvHD occurred in 15.8% and 10.5% of patients in the conventional group, respectively. No transplant‐related mortality or thrombotic events occurred.
Conclusion
This study, representing the largest reported experience with PTCy‐based HSCT for PNH, suggests that this platform is feasible and associated with excellent survival and a promising GvHD profile. These preliminary findings support further investigation of PTCy in transplant strategies for PNH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Hematology, Hunan Provincial People's Hospital, Changsha, Hunan, China.
- Department of Hematology, First People's Hospital of Chenzhou, Chenzhou, Hunan, China.
- Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Ultrasound Imaging, Xiangya Hospital, Central South University, Changsha, Hunan, China.
ORCID-Profile: Yan Chen, Can Liu, Xin Li, Zhongqing Wang, Bin Fu
Zitieren
APA
Weng, Q., Xu, Y., Chen, Y., Liu, C., Zhu, P., Deng, M., Li, X., Nie, L., Wang, Z., & Fu, B. (2026). Allogeneic Hematopoietic Cell Transplantation Using Post‐Transplant Cyclophosphamide in Patients With Large Paroxysmal Nocturnal Hemoglobinuria Clones. European Journal of Haematology, 117(1), 154-160. https://doi.org/10.1111/ejh.70162
Vancouver
Weng Q, Xu Y, Chen Y, Liu C, Zhu P, Deng M, et al. Allogeneic Hematopoietic Cell Transplantation Using Post‐Transplant Cyclophosphamide in Patients With Large Paroxysmal Nocturnal Hemoglobinuria Clones. European Journal of Haematology. 2026;117(1):154-160. doi:10.1111/ejh.70162
BibTeX
@article{Weng2026,
author = {Weng, Qiangsheng and Xu, Yajing and Chen, Yan and Liu, Can and Zhu, Ping and Deng, Mingyang and Li, Xin and Nie, Ling and Wang, Zhongqing and Fu, Bin},
title = {Allogeneic Hematopoietic Cell Transplantation Using Post‐Transplant Cyclophosphamide in Patients With Large Paroxysmal Nocturnal Hemoglobinuria Clones},
journal = {European Journal of Haematology},
year = {2026},
volume = {117},
number = {1},
pages = {154--160},
doi = {10.1111/ejh.70162}
}
EUVIMED